36 results about "Isopropyl formate" patented technology

The present invention relates to 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methyl-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

The present invention relates to 4-[5-Methoxy-6-(2-methyl-6-[1,2,4]triazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

Pesticide composition comprising as active ingredients at least one specific imidazole compound and at least one fungicide, wherein the fungicide is selected from (S)-5-methyl-2-methylthio-5- Phenyl-3-phenylamino-3,5-dihydroimidazol-4-one, 2-methyl-1-[(1-p-tolylethyl)carbamoyl]-(S)-propylamino Isopropyl formate, 3,5-dichloro-N-(3-chloro-1-ethyl-1-methyl-2-oxopropyl)-4-methylbenzamide and N-(α- Cyano-2-thienyl)-4-ethyl-2-(ethylamino)-5-thiazolecarbamoyl.

The invention discloses a pharmaceutical composition for treating obesity-related diseases. The composition contains a therapeutically-effective amount of 1-isopropyl-1'-(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-carbonyl)-4,6-dihydrospiro[indazol-5,4'-piperidine]-7(1H)-one and a therapeutically-effective amount of 4-[5-cyano-4-({2-fluoro-4-[(2-hydroxyethyl) sulfonyl]phenoxy}methyl)-1H-pyrazol-1-yl]piperidin-1-isopropyl formate which have the mass ratio of (3: 1) to (1: 3). By using the two kinds of drugs in a combined manner, symptoms, such as hypertension and diabetes, caused by obesity can be treated while the obesity is treated.

The invention relates to a preparation method of crystal form I linezolid. The method comprises the steps of: adding a linezolid crude product, non-crystal form I linezolid or mixed linezolid crystal into an ester or toluene solvent, wherein the ester solvent is any one selected from ethyl acetate, acetic acid isobutyl ester, tert-butyl acetate, acetic acid isopropyl ester, isopropyl formate, or ethyl formate, and the amount ratio of the ester or toluene solvent to the linezolid crude product, the non-crystal form I linezolid or the mixed linezolid crystal is (5-40mL): 1g; heating and dissolving the linezolid crude product, the non-crystal form I linezolid or the mixed linezolid crystal into the solvent, and cooling to separate out crystal; filtering the mixed liquid; and finally, washing a filter cake by an organic solvent and drying to obtain the crystal form I linezolid. The preparation method of the crystal form I linezolid is less in solvent amount, does not need crystal nucleus induction, only needs dissolving by heating, cooling and filtering, and is simple and convenient to operate and mild in conditions, thus the preparation method is suitable for industrial production; meanwhile, the method is high in yield.

The oxidation of isobutyraldehyde produces isobutyric acid and byproducts, such as isopropyl formate. A process of reducing the isopropyl formate byproduct and other byproducts in the oxidation of isobutyraldehyde is described. The process uses a carbonyl compound, such as acetone, to reduce byproduct levels in the resulting product. Process for use of static mixers in oxidation reactions of aldehydes are also provided.

The oxidation of isobutyraldehyde produces isobutyric acid and byproducts, such as isopropyl formate. A method of reducing the isopropyl formate byproduct in the oxidation of isobutyraldehyde is described. The method uses a co-solvent, such as acetone, to the isobutyraldehyde feed to increase both the selectivity of the reaction to isobutyric acid and the production rate of isobutyric acid so that the isopropyl formate byproduct is significantly reduced.

The invention relates to a preparation method of azelnidipine, belongs to the field of medicines and opens up a new way for synthesizing dihydropyridine calcium antagonists. With cyanoacetic acid as a raw material, the method comprises the following sequential steps: synthesizing isopropyl 2-amino-3-carboxyl-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-5-formate through a Pinner reaction and a Hantzsch reaction; and performing DCC dehydration esterification with 1-diphenylmethyl-3-hydroxyl azetidine hydrochloride to obtain a crude product of azelnidipine; and performing further crystal transformation to obtain alpha-crystal type azelnidipine.

Pesticide composition comprising as active ingredients at least one specific imidazole compound and at least one fungicide, wherein the fungicide is selected from (S)-5-methyl-2-methylthio-5- Phenyl-3-phenylamino-3,5-dihydrimidazol-4-one, 2-methyl-1-[(1-p-tolylethyl)carbamoyl]-(S)-propylamino Isopropyl formate, 3,5-dichloro-N-(3-chloro-1-ethyl-1-methyl-2-oxopropyl)-4-methylbenzamide and N-(α- Cyano-2-thienyl)-4-ethyl-2-(ethylamino)-5-thiazolecarbamoyl.

The invention relates to a method for synthesizing a 3, 3-dimethoxy cyclobutane-1, 1-isopropyl diformate compound IV, and the reaction is as follows: M is selected from potassium, sodium, lithium, calcium and magnesium; comprising the following steps: (1) carrying out salt forming reaction on a compound shown as a formula I in an organic solvent in the presence of alkali, and filtering after the reaction is completed to obtain a solid compound shown as a formula II; and (2) carrying out ring closing reaction on the solid compound as shown in the formula II and a compound as shown in a formula III in an aprotic solvent in the presence of a catalyst to obtain a compound as shown in a formula IV. The method is simple in synthesis route, mild in process condition, simple and convenient to operate, high in yield and good in product purity, solves the technical problems of tar impurities and alcohol ester exchange byproducts in the prior art, and is suitable for industrial large-scale production.

The invention provides a method for preparing cyclopropanecarboxylic acid by using a heteropolyacid catalyst. The method comprises the following steps: adding 192g of isopropyl cyclopropanecarboxylateinto a flask, adding 54g of water, uniformly carrying out stirring, adding 1-10% of the heteropolyacid catalyst, uniformly carrying out stirring, then carrying out a reaction at room temperature for2 hours, carrying out filtering after the reaction is ended, collecting the heteropolyacid catalyst for reuse, carrying out normal-pressure distillation on the obtained mother liquor, and collecting fractions at a temperature of 80-82 DEG C to obtain the cyclopropanecarboxylic acid. According to the invention, the catalyst with relatively good selectivity is selected, so that generation of a largeamount of salt-containing wastewater can be avoided, the catalyst can be reused and can be easily separated from the system, the yield is relatively high, and the novel catalyst adopted in the process has low corrosion to equipment.

The invention discloses structural filter cores and specifically relates to a structural filter core for removing benzene from drinking water and a preparation method thereof. In the preparation process of the structural filter core, a certain amount of 180-mesh bentonite is weighed according to ratio of raw materials, sodium sulfide is added in the bentonite, and activation is carried out for 120-240min at the temperature of 120-180 DEG C; the activated mixture is mixed with polyvinyl chloride, a certain amount of azodicarboxylate isopropyl is then added and mixed to be even; and the mixture is put in a columnar mold, sintered at the temperature of 320-400 DEG C and molded after about 210-300min, and demolded till being cooled by airing, and then, the columnar filter core with the pore diameter of 3mm to 5mm and the porosity factor of 30% to 40% is formed. The structural filter core not only purifies the drinking water, but also avoids the injury to human bodies arising from excessive benzene in the drinking water, thereby being very applicable to the treatment of drinking water at home terminals. Proved by test, the structural filter core can have a ratio of over 99.9% in the removal of the benzene in the drinking water.

The invention discloses application of a composition in preparation of a medicine for treating obesity. The composition contains a therapeutically-effective amount of 1-isopropyl-1'-(1-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-carbonyl)-4,6-dihydrospiro[indazol-5,4'-piperidine]-7(1H)-one and a therapeutically-effective amount of 4-[5-cyano-4-({2-fluoro-4-[(2-hydroxyethyl)sulfonyl]phenoxy}methyl)-1H-pyrazol-1-yl]piperidin-1-isopropyl formate which have the mass ratio of (3: 1) to (1: 3). By using the two kinds of drugs in a combined manner, symptoms, such as hypertension and diabetes, caused by the obesity can be treated while the obesity is treated.

The invention discloses a preparation method of sodium salt of pravastatin, which comprises the following steps: adding inorganic alkaline or organic alkaline containing sodium ions as positive ions into organic solution containing the pravastatin until pH is more than 7 and obtaining sodium pravastatin; the organic solution containing the pravastatin comprises the pravastatin and first solvent, wherein the first solvent is selected from one or a plurality of methyl formate, n-propyl formate, isopropyl formate, n-butyl formate, methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, sec-butyl acetate, isobutyl acetate and tert-butyl acetate.

The present invention relates to 4-[5-methyl-6-(2-methyl-pyridin-3-yloxy)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.

The invention discloses a pharmaceutical composition for treating type 2 diabetes. The pharmaceutical composition contains a therapeutically-effective amount of 1'-(1H-indazol-5-carbonyl)-1-isopropyl-4,6-dihydrospiro[indazol-5,4'-piperidine]-7(1H)-one and a therapeutically-effective amount of 4-[5-cyano-4-({2-fluoro-4-[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]phenoxy}methyl)-1H-pyrazol-1-yl]piperidin-1-isopropyl formate which have the mass ratio of (3: 1) to (1: 3). The pharmaceutical composition can be used for effectively treating the type 2 diabetes.

The invention discloses an asphalt concrete snow-melting and ice-inhibiting pavement structure. The pavement structure sequentially comprises a snow-melting and ice-inhibiting asphalt concrete surfacelayer, an impermeable layer, a stress absorption layer, a gravel layer and a base layer from top to bottom, wherein the snow-melting and ice-inhibiting asphalt concrete surface layer is formed by mixing an asphalt mixture and a snow-melting and ice-inhibiting material and paving; the stress absorption layer is formed by mixing and paving rubber and asphalt; wherein the asphalt is SBS modified asphalt, and the snow-melting and ice-inhibiting raw materials comprise biochemical humic acid, pyroligneous liquor, a starch-acrylic acid grafted copolymer, chloroprene emulsion, epoxy resin, phthalimide, isopropyl benzoate, polyester acrylate, beta-hydroxybutyraldehyde, thiourea, sorbitan fatty acid ester and the like. And after the snow-melting and ice-inhibiting material is mixed with the pavement material, the pavement performance of the pavement material can be improved, the loss of part of the snow-melting and ice-inhibiting material cannot be caused by rainwater scouring and vehicle abrasion, and a long-term effect can be achieved.

The invention provides a battery foil rolling additive as well as a preparation method and application thereof. The battery foil rolling additive comprises the following components in percentage by mass: 10-20% of fatty acid ester, 15-30% of fatty alcohol, 45-65% of an adamantane compound and 0.1-5% of an extreme pressure additive, wherein the mass percentage content of dihydroxy adamantane isopropyl formate in the adamantane compound is 50 to 100 percent. According to the battery foil rolling additive, through matching of the components, especially the use of the adamantane compound with a specific molecular structure, the battery foil rolling additive has excellent lubricating performance, the surface quality of a rolled battery foil can be improved, the surface dyne value of the battery foil is increased, and the cost of a corona process is reduced; and meanwhile, the use of the battery foil rolling additive is beneficial to improving the dispersing performance and filtering efficiency of aluminum powder and improving the cleaning performance of a rolling mill.

The invention discloses the technical field of an aspartame production process, and particularly relates to an aspartame production process which comprises the following steps: adding formic acid and magnesium oxide into a reaction kettle, stirring to completely dissolve magnesium oxide in formic acid, then adding acetic anhydride, isopropanol, L-phenylalanine and ethyl acetate into the reaction kettle, stirring at normal temperature, and when a reaction solution is viscous, stopping stirring to obtain an aspartame solution; acetic acid and the like are added, isopropyl alcohol is added into reactants to react with formic acid to generate isopropyl formate, and formic acid is removed, so that smooth proceeding of subsequent condensation reaction is guaranteed, and the yield of the final product aspartame is effectively improved; after the condensation reaction is finished, the solvent acetic acid is volatilized in advance in a centrifugal manner, so that most acetic acid is removed, the acetic acid and ester are removed by adding hydrochloric acid and methanol into the reaction kettle in a reduced pressure distillation manner, the methanol, residual acetic acid and hydrolyzed formic acid generate ester, and the ester is removed through distillation. And the high purity of the final product aspartame is ensured through multiple removal processes of the solvent.

The reaction kettle structure comprises a kettle body, a liquid pump is arranged at the outer top of the kettle body, an air pump is arranged at the outer bottom of the kettle body, a liquid inlet of the liquid pump is communicated with a liquid conveying pipeline, a liquid outlet of the liquid pump is communicated with a liquid inlet pipe, and the tail end of the liquid inlet pipe downwards extends into the kettle body and is rotationally connected with a liquid spraying pipe. The peripheral side of the lower part of the liquid spraying pipe is communicated with a plurality of liquid spraying branch pipes, the bottom ends of the liquid spraying pipe and the liquid spraying branch pipes are communicated with liquid spraying nozzles, an air inlet of the air pump is communicated with an air conveying pipeline, an air outlet of the air pump is communicated with an air inlet pipe, and the tail end of the air inlet pipe upwards extends into the kettle body and is rotationally connected with an air spraying pipe; a guide rail is arranged on the top in the kettle body, an electric sliding block is arranged on the guide rail in a sliding mode, the bottom end of the electric sliding block is fixedly connected with an L-shaped connecting rod, and the tail end of the connecting rod is fixedly connected with a rotating frame. According to the utility model, the hedging contact of alcohol and phosgene and efficient and high-quality stirring can be realized, and the reaction efficiency and quality are higher.

The oxidation of isobutyraldehyde produces isobutyric acid and byproducts, such as isopropyl formate. A process of reducing the isopropyl formate byproduct and other byproducts in the oxidation of isobutyraldehyde is described. The process uses a carbonyl compound, such as acetone, to reduce byproduct levels in the resulting product. Process for use of static mixers in oxidation reactions of aldehydes are also provided.

The invention discloses a method for detecting formic acid, methanol and ethanol based on an automatic headspace gas chromatography-mass spectrometry technology. The detection method comprises the following steps: S1, preparing a mixed standard working solution of formic acid, methanol and ethanol; s2, adding an esterification reagent into the mixed standard working solution or the to-be-detected sample, and sealing the mixed standard working solution or the to-be-detected sample in a headspace bottle; s3, the headspace bottle is placed in an automatic headspace sampler, heating and heat preservation are conducted, formic acid and isopropanol are subjected to an esterification reaction to generate isopropyl formate, and meanwhile the isopropyl formate, methyl alcohol and ethyl alcohol are volatilized to the top space of the headspace bottle; s4, the headspace sample injector automatically extracts gas in the headspace and injects the gas into the gas chromatography system; and S5, carrying out separation through a chromatographic column, carrying out heating, carrying out detection by using a mass spectrometry detector, and carrying out qualitative and quantitative analysis on formic acid, methanol and ethanol in the to-be-detected sample. The detection method provided by the invention realizes rapid, automatic, high-sensitivity and high-specificity synchronous detection of formic acid, methanol and ethanol in a blood sample.

The invention discloses a preparation method of sodium salt of pravastatin, which comprises the following steps: adding inorganic alkaline or organic alkaline containing sodium ions as positive ions into organic solution containing the pravastatin until pH is more than 7 and obtaining sodium pravastatin; the organic solution containing the pravastatin comprises the pravastatin and first solvent, wherein the first solvent is selected from one or a plurality of methyl formate, n-propyl formate, isopropyl formate, n-butyl formate, methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, sec-butyl acetate, isobutyl acetate and tert-butyl acetate.

The invention discloses a synthesis method of diisopropyl azodicarboxylate. The synthesis method comprises the following steps: (1) adding alkali and a solvent under protection of inert gases, sequentially adding carbazic acid isopropyl ester and diethyl carbonate, carrying out heating reaction at 100-180 DEGC for 2-6 hours, adjusting the pH value of a solution to 4.5-7.5 with acid, and carrying out suction filtration, so as to obtain hydrogenated diisopropyl azodiformate; and (2) adding 40%-50% of sulfuric acid solution to the hydrogenated diisopropyl azodiformate at -20 DEG C to 25 DEG C, dissolving, adding a catalyst, controlling the reaction temperature to -15 DEG C to -5 DEG C, dropwise adding 10%-15% of hydrogen peroxide until no heat is emitted, further reacting for 5-10 hours after dropwise adding is ended, quenching, extracting, washing to be neutral, drying, filtering, and concentrating to obtain the diisopropyl azodiformate. The synthesis method disclosed by the invention is clean and environmental friendly in raw material, mild in reaction condition, and few in byproducts; and the product is high in yield and beneficial to industrialized production.

The oxidation of isobutyraldehyde produces isobutyric acid and byproducts, such as isopropyl formate. A method of reducing the isopropyl formate byproduct in the oxidation of isobutyraldehyde is described. The method uses a co-solvent, such as acetone, to the isobutyraldehyde feed to increase both the selectivity of the reaction to isobutyric acid and the production rate of isobutyric acid so that the isopropyl formate byproduct is significantly reduced.

The oxidation of isobutyraldehyde produces isobutyric acid and byproducts, such as isopropyl formate. A process of reducing the isopropyl formate byproduct and other byproducts in the oxidation of isobutyraldehyde is described. The process uses a carbonyl compound, such as acetone, to reduce byproduct levels in the resulting product. Process for use of static mixers in oxidation reactions of aldehydes are also provided.

The invention discloses application of a composition in preparation of a medicine for treating liver insulin resistance. The composition contains a therapeutically-effective amount of 1'-(1H-indazol-5-carbonyl)-1-isopropyl-4,6-dihydrospiro[indazol-5,4'-piperidine]-7(1H)-one and a therapeutically-effective amount of 4-[5-cyano-4-({2-fluoro-4-[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]phenoxy}methyl)-1H-pyrazol-1-yl]piperidin-1-isopropyl formate which have the mass ratio of (3: 1) to (1: 3). Proved by experiments, by using the two kinds of drugs in a combined manner, the liver insulin resistance can be effectively treated, and concomitant symptoms, such as hypertension and diabetes, can be treated while the liver insulin resistance is treated.

The invention discloses a SBS grafted type deodorizing mattress spray glue and a preparation method thereof, comprising the following components in parts by weight: 10-15 parts of methyl isobutyl ketone; 5-10 parts of isopropyl formate; aromatics 10-20 parts of environmentally friendly solvent oil; 15-25 parts of methylcyclohexane; 10-18 parts of SBS elastomer; 0.1-0.5 parts of BPO; 5-15 parts of MMA; 0-8 parts of BA; 1-3 parts of terminator; 10-15 parts of hydrogenated petroleum resin; 12-18 parts of hydrogenated rosin modified resin. The SBS grafted odor-free mattress spray glue of the present invention is colorless and transparent, has strong adhesive force, is resistant to yellowing, chalking, high temperature, oil, plasticizer, non-toxic, odorless and residue-free. It is an ideal glue spraying choice for mattress manufacturers. During the spraying process, the odor is small, and the film has no residual solvent and resin odor. The film is white and transparent. After sizing, it will not pollute light-colored mattress fabrics.

The invention discloses a method for determining the residual contents of 4-methyl piperazine-1-methyl formate, 4-methyl piperazine-1-ethyl formate and 4-methyl piperazine-1-isopropyl formate in zopiclone. The method comprises the following steps: preparing a contrast solution: precisely weighing a proper amount of methyl 4-methylpiperazine-1-formate, a proper amount of ethyl 4-methylpiperazine-1-formate and a proper amount of isopropyl 4-methylpiperazine-1-formate, putting the weighed materials into a volumetric flask, dissolving the weighed materials with acetonitrile, diluting the dissolved materials, and respectively preparing 125ng / mL limit concentration solutions; preparing a test sample solution: precisely weighing a proper amount of zopiclone test sample, placing the zopiclone test sample in a volumetric flask, dissolving and diluting the zopiclone test sample with acetonitrile, and preparing the zopiclone test sample into a 1mg / mL solution; and sample determination: respectively taking the test solution and the reference solution, directly injecting the test solution and the reference solution into a GCMS, recording a chromatogram, and calculating by peak areas according to an external standard method to obtain the contents of the 4-methylpiperazine-1-methyl formate, the 4-methylpiperazine-1-ethyl formate and the 4-methylpiperazine-1-isopropyl formate in the test solution.